Biogen Inc. Q1 2025 10-Q Filed
Ticker: BIIB · Form: 10-Q · Filed: May 1, 2025 · CIK: 875045
| Field | Detail |
|---|---|
| Company | Biogen Inc. (BIIB) |
| Form Type | 10-Q |
| Filed Date | May 1, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotechnology, revenue
TL;DR
Biogen Q1 2025 10-Q is in, check revenue for anti-CD20 and LEQEMBI.
AI Summary
Biogen Inc. filed its 10-Q for the period ending March 31, 2025. The company reported revenues from its anti-CD20 therapeutic programs and LEQEMBI collaboration. Specific financial figures for these segments and overall product revenues for Q1 2025 and Q1 2024 are detailed within the filing.
Why It Matters
This filing provides investors with the latest financial performance data for Biogen, including revenue breakdowns for key therapeutic areas and collaborations, crucial for assessing the company's current financial health and future prospects.
Risk Assessment
Risk Level: medium — Biogen operates in the highly regulated and competitive pharmaceutical industry, facing risks related to drug development, clinical trials, regulatory approvals, and market competition.
Key Numbers
- 146,527,832 — Shares (Total shares outstanding as of the reporting period.)
Key Players & Entities
- BIOGEN INC. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250501 (date) — Filing date
- 225 BINNEY STREET, CAMBRIDGE, MA 02142 (address) — Company's business and mailing address
- LEQEMBI (product) — Key collaboration mentioned
FAQ
What were Biogen's total revenues for the first quarter of 2025?
The filing details revenues for specific segments like anti-CD20 therapeutic programs and LEQEMBI collaboration for Q1 2025, but a consolidated total revenue figure for the quarter is not explicitly stated in the provided snippet.
How do Q1 2025 revenues from anti-CD20 therapeutic programs compare to Q1 2024?
The filing indicates that revenues from anti-CD20 therapeutic programs for the period January 1, 2025, to March 31, 2025, are reported, and comparative data for the period January 1, 2024, to March 31, 2024, is also available for comparison.
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20250331, meaning the filing covers the period ending March 31, 2025.
When was this 10-Q filing submitted to the SEC?
The filing was submitted on 20250501.
What is the company's primary business classification?
Biogen Inc. is classified under BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 1, 2025 regarding BIOGEN INC. (BIIB).